1.Zhu Y﹟, Li H﹟, Hu L, Wang J, Zhou Y, Pang Z, Liu L, Shao F. Structure of a Shigella Effector Reveals a Novel Class of Ubiquitin Ligases. Nature Structural & Molecular Biology, 2008, 15: 1302-1308. (IF:12.2)
2.Zhu Y﹟, Li H﹟, Long C﹟, Hu L, Xu H, Liu L, Chen S, Wang D, Shao F. Structure insights into the enzymatic mechanism of the pathogenic MAPK phosphothreonine lyase. Molecular Cell, 2007, 28: 899-914. (IF:14.6)
3.Zhang J , Shao F , Li Y , Cui H , Chen L, Li H, Zou Y, Long C, Lan L, Chai J, Chen S, Tang X, Zhou J. A Pseudomonas syringae Effector Inactivates MAPKs to Suppress PAMP-Induced Immunity in Plants. Cell Host and Microbe, 2007; 1: 175-185. (IF:13.0)
4.Li H﹟, Xu H﹟, Zhou Y﹟, Zhang J, Long C, Li S, Chen S, Zhou J, Shao, F. The phosphothreonine lyase activity of a bacterial type III effector family. Science. 2007; 315: 1000-1003. (IF:29.7)
5.Du H, Li H, Zhang F, Lin X, Shi J, Shi Y, Ji L, Hu J, Lin D, Hu H. Acceleration of alpha-synuclein aggregation by homologous peptides. FEBS Lett. 2006;580: 3657-64.
6.Tang L, Li H, Du H, Zhang F, Hu X, Hu H. Study of the disassembly-assembly process of alpha-synuclein fibrils by in situ atomic force microscopy. Micron. 2006, 37: 675-9.
7.Li H, Lin D, Luo X, Zhang F, Ji L, Du H, Song G, Hu J, Zhou J, Hu H.Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 2005; 272: 3661-72.
8.Du H, Tang L, Luo X, Li H, Hu J, Zhou J, Hu H. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry. 2003; 42: 8870-8.
9.Li H, Du H, Tang L, Hu J, Hu H. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation. Biopolymers. 2002; 64: 221-6.
﹟equal contribution